Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Closed

0.8 1.27

Buy Sell

Overview

Share price change

24h

Current

Min

0.79

Max

0.8

Key metrics
By Trading Economics
Income	418K -5.5M
EPS	-0.18
Profit margin	-6,600
Employees	25
EBITDA	906K -5.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+400% upside

Dividends
By Acuity
Next Earnings	13 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-12M 25M
Previous open	-0.47
Previous close	0.8

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Aug 2026, 23:52 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower, reaching its lowest point in a month amid cautious market sentiment and correlated asset declines.

9 Aug 2026, 23:51 UTC

Bitcoin and Ethereum decline amid bearish sentiment, while U.S. labor data sparks record highs in equity markets and lowers Fed rate hike expectations.

9 Aug 2026, 23:51 UTC

Singapore's markets closed for National Day; Japan's BOJ releases opinions, while China's inflation and PPI growth fall short of expectations, raising economic stability concerns.

9 Aug 2026, 23:51 UTC

U.S. equity markets rally as disappointing July jobs data lowers Fed rate hike expectations, while Bitcoin and Ethereum decline amid cautious investor sentiment.

9 Aug 2026, 23:51 UTC

Singapore's markets closed for National Day; Japan's monetary policy remains unclear while China's inflation drops to 0.5%, raising deflation concerns.

9 Aug 2026, 23:51 UTC

Retail Sales Ex Autos Expected to Rise 0.2% in July Amid Mixed Economic Signals

9 Aug 2026, 23:51 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.5% Amid Mixed Market Sentiment and Geopolitical Concerns

9 Aug 2026, 23:51 UTC

Japan's GDP Growth Forecasted at 0.02% for Q2 Amid Mixed Economic Sentiment and Global Uncertainties

9 Aug 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading lower during the session, reflecting cautious market sentiment amid slight declines in Ethereum and minimal hedge fund re-grossing in AI themes.

9 Aug 2026, 23:41 UTC

BoJ Summary of Opinions Release Expected to Clarify Interest Rate Outlook Amidst Mixed Market Sentiment and Global Economic Trends.

9 Aug 2026, 23:41 UTC

Japan's June current account data expected to show a significant surplus decline, raising concerns about economic challenges and impacting financial markets.

9 Aug 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.1% in August Amid Cautious Consumer Sentiment and Economic Uncertainty

9 Aug 2026, 23:31 UTC

Market Awaits July 2026 PPI Release Amid Mixed Inflation Signals and Potential Deflationary Pressures.

9 Aug 2026, 23:31 UTC

Correlated Moves

Cardano is declining in today's session, continuing a downward trend observed since Saturday. The asset's movement reflects broader bearish sentiment in the market.

9 Aug 2026, 23:21 UTC

Core Producer Prices Expected to Rise 0.2% Amid Slower Inflation and Cautious Investor Sentiment Ahead of August Release

9 Aug 2026, 23:01 UTC

Palladium is trading lower during Sunday’s session, despite earlier gains. The asset remains above its 20-day moving average and near a one-month high.

9 Aug 2026, 23:01 UTC

Silver has been gaining since Friday's close, currently above its 20-day moving average. The asset reached a session high before pulling back slightly.

9 Aug 2026, 23:01 UTC

Silver/CAD is trading higher since Friday's close, reflecting a cumulative return of 0.17%. The price remains above its 20-day moving average.

9 Aug 2026, 23:01 UTC

Gold/SGD is trading roughly flat, remaining above its 20-day moving average and near the upper end of its one-month range.

9 Aug 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, reflecting volatility earlier in the session. The asset remains above its 20-day moving average and near its one-month range's upper end.

9 Aug 2026, 23:01 UTC

The US 2Y Treasury Bond Index is trading higher, remaining steady near the upper end of its one-month trading range. No specific news was identified.

9 Aug 2026, 23:01 UTC

Correlated Moves

Gold/JPY is advancing, reflecting a positive trend since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

9 Aug 2026, 23:01 UTC

Gold and silver are trading lower, continuing a downward trend since Friday's close. The assets briefly rebounded earlier in the session.

9 Aug 2026, 23:01 UTC

Correlated Moves

Gold/GBP is trading roughly flat, influenced by a slight increase in Silver. Market sentiment remains cautious amid minimal hedge fund re-grossing within AI themes.

9 Aug 2026, 23:01 UTC

Silver/NZD is higher today, maintaining a position above its 20-day moving average after pulling back from earlier session highs. No specific news was identified.

9 Aug 2026, 23:01 UTC

Silver/JPY is trading higher today, maintaining a position above its 20-day moving average. The asset showed fluctuations earlier in the session.

9 Aug 2026, 23:01 UTC

Silver/HKD is higher during Sunday’s session, continuing its positive momentum from Friday. The asset remains above its 20-day moving average.

9 Aug 2026, 23:01 UTC

Correlated Moves

Gold/CHF is trading roughly flat, maintaining stability after a slight increase in correlation with silver amid cautious market sentiment and hedge fund activity.

9 Aug 2026, 23:01 UTC

Silver/SGD is advancing during the ongoing session, remaining above its 20-day moving average and near the upper end of its one-month range.

9 Aug 2026, 23:01 UTC

Gold/HKD is trading roughly flat, remaining 6.16% above its 20-day moving average and near the upper end of its one-month range.

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

400% upside

12 Months Forecast

Average 4 USD 400%

High 4 USD

Low 4 USD

Based on 1 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.